Hydromethylthionine (dihydrobromide)

Hydromethylthionine dihydrobromide (Leukomethylene blue dihydrobromide) is a potent inhibitor of TAU protein aggregation. Hydromethylthionine dihydrobromide reduces neurodegeneration by interacting with TAU proteins and preventing them from forming neurotoxic aggregates. Hydromethylthionine dihydrobromide can be used in the study of Alzheimer's disease and other TAU related disorders[1].

Product Specifications

CAS Number

[951131-15-0]

Product Name Alternative

Leukomethylene blue (dihydrobromide) ; LMTM (dihydrobromide)

UNSPSC

12352005

Hazard Statement

H302-H315-H319-H335

Target

Tau Protein

Type

Reference compound

Related Pathways

Neuronal Signaling

Applications

Neuroscience-Neurodegeneration

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/hydromethylthionine-dihydrobromide.html

Smiles

CN(C)C1=CC(SC2=CC(N(C)C)=CC=C2N3)=C3C=C1.Br.Br

Molecular Formula

C16H21Br2N3S

Molecular Weight

447.23

Precautions

P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501

References & Citations

[1]Kondak C, et al. Hydromethylthionine enhancement of central cholinergic signalling is blocked by rivastigmine and memantine[J]. Journal of neurochemistry, 2022, 160 (2) : 172-184.